Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir
暂无分享,去创建一个
H. Mo | T. Cihlar | E. Svarovskaia | Ross Martin | Jason K. Perry | D. Porter | Jiani Li | Aiyippa Parvangada
[1] N. Krogan,et al. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant , 2021, bioRxiv.
[2] Sergei L. Kosakovsky Pond,et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa , 2020, medRxiv.
[3] M. Koopmans,et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans , 2020, Science.
[4] D. Tegunov,et al. Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir , 2020, bioRxiv.
[5] Vineet D. Menachery,et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19 , 2020, Nature Communications.
[6] R. Jordan,et al. Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases , 2020, Proceedings of the National Academy of Sciences.
[7] Joy Y. Feng,et al. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action , 2020, The Journal of Biological Chemistry.
[8] O. Tsang,et al. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. , 2020, JAMA.
[9] B. Chait,et al. Structural Basis for Helicase-Polymerase Coupling in the SARS-CoV-2 Replication-Transcription Complex , 2020, Cell.
[10] B. Chait,et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex , 2020, bioRxiv.
[11] R. Baric,et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice , 2020, Cell Reports.
[12] R. Bruno,et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 , 2020, The New England journal of medicine.
[13] L. Dodd,et al. Remdesivir for the Treatment of Covid-19 — Final Report , 2020, The New England journal of medicine.
[14] R. Berisio,et al. A Structural View of SARS-CoV-2 RNA Replication Machinery: RNA Synthesis, Proofreading and Final Capping , 2020, Cells.
[15] S. Anzick,et al. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.
[16] Joy Y. Feng,et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.
[17] H. Feldmann,et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection , 2020, Proceedings of the National Academy of Sciences.
[18] E. Holmes,et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.
[19] G. Gao,et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.
[20] R. Baric,et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV , 2020, Nature Communications.
[21] A. Ward,et al. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors , 2019, Nature Communications.
[22] Xiaotao Lu,et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease , 2018, mBio.
[23] Clemens Vonrhein,et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA , 2017, Proceedings of the National Academy of Sciences.
[24] Lisa E. Gralinski,et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.
[25] A. Arvey,et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.
[26] Stefan Elbe,et al. Data, disease and diplomacy: GISAID's innovative contribution to global health , 2017, Global challenges.
[27] William A. Lee,et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.
[28] K. Katoh,et al. MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.